Lyra Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OTC.Pink
Lyra Therapeutics, a clinical-stage biotech, announced the suspension of its lead drug candidate LYR-210 development, a significant workforce reduction, and its delisting from Nasdaq, as it explores strategic alternatives amidst substantial financial losses.
OTC.Pink
Lyra Therapeutics' future hangs in the balance as it seeks strategic alternatives following a failed Phase 3 trial, workforce reduction, and ongoing financial challenges.
OTC.Pink
Lyra Therapeutics' 10-K filing details its capital structure, shareholder rights, and corporate governance policies, alongside updates on its clinical programs.